Lupin commences business
Lupin Laboratories Pvt. Ltd. is incorporated
First Formulations Plant and R&D Center at Aurangabad is commissioned
Starts the production of Ethambutol
The Cephalexin plant at Mandideep and 7 ADCA plants at Ankleshwar go on stream
Lupin Human Welfare and Research Foundation (LHWRF) is founded by Desh Bandhu Gupta
Receives US FDA approvals for Ankleshwar and Mandideep plants
Initiates production of Injectable Cephalosporins (API and Finished Product) at Mandideep
Establishes a Fermentation plant at Lupin Chemicals Ltd. Tarapur, Maharashtra
IPO of Lupin Laboratories Ltd. and Lupin Chemicals Ltd.
US FDA approval for three plants – Cefaclor at Mandideep, 7 ACCA at Ankleshwar and Rifampicin at Tarapur
Receives U.K. MCA approval for the Injectable Cephalosporin Finished Product Plant at Mandideep
Receives U.K. MCA approval for the Injectable Cephalosporin API plant at Mandideep
Receives US FDA approval for Injectable Cefotaxime (API and Finished Product) at Mandideep
State-Of-The-Art R&D centre, Lupin Research Park at Pune is commissioned
Commences supply of Cephalosporin Finished Product to its Alliance Partners in the U.S.
Lupin Laboratories Ltd. is amalgamated with Lupin Chemicals Ltd., and retitled as Lupin Ltd.
Exports to Advanced Markets cross INR 1000 Mn
Patent filings cross 100
First five ANDAs filed
New Anti-TB Facility commissioned at Aurangabad
Rablet rated by ORGMarg as the second best launch of FY03
Receives WHO approval for finished dosage facility at Aurangabad
Successfully implements SAP ERP across the company to unify all business functions and processes
Receives U.S. FDA approval for the Oral Cephalosporin Plant at Mandideep
Lupin Pharmaceuticals Inc. U.S., formed for commercialization activities in the U.S.
Commences U.S. Branded Business with the launch of Suprax®
Receives US FDA approval for New Lovastatin Plant at Tarapur
Receives US FDA approval for Goa Finished Dosage facility
Launches its Generics Business in the U.S. with four Products
Implements maiden Employees Stock Option Plan
Receives MHRA (U.K.) and WHO approval for Goa finished dosage facility
Maiden bonus shares issued in the ratio of 1:1
Maiden Issue of Foreign Currency Convertible Bonds (FCCB) aggregating USD 100 Mn
Acquires Kyowa Pharmaceutical Industry Company Ltd., a leading Generics Company in Japan
Acquires Vadodara based Rubamin Laboratories Ltd.
Starts commercial production at the new Finished Dosage Facility at Jammu
Sets up a Biotech Facility at Pune
Expands its product basket in Japan-Kyowa and receives approvals for ten products from the Ministry of Health & Labour Welfare, Japan
Acquires Hormosan Pharma Gmbh in Germany
Acquires majority stake in Generic Health Pty Ltd., Australia
Acquires majority stake in Pharma Dynamics, South Africa
Acquires the U.S. Rights for Antara®
Acquires majority stake in Multicare Pharmaceuticals Philippines INC.
Starts Commercial Production at the New Oral Solid Dosage Facility at Pithampur
Acquires I’Rom Pharmaceuticals in Japan
Enters the Nifty 50 Index
Inks Strategic Joint Venture Agreement with Yoshindo Inc. in Japan to launch biosimilars
Acquires Laboratorios Grin S.A. De C.V., Mexico, Specialty Ophthalmic Company and with this enters The Latin American Market
Acquires Nanomi B.V. to enter the Complex Injectables Space
Center of Excellence for Inhalation Research in Coral Springs, Florida is inaugurated
Acquires the Specialty Product Portfolio of Temmler Pharma GmbH & Co. in Germany
Acquires Medquimica Industria Farmaceutica S.A. in Brazil
Completes the acquisition of Pharma Dynamics in South Africa
Commissions a new plant at Tottori, Japan
Bolsters the U.S. Brands Portfolio with Methergine® Oral Tablets
Acquires Branded Product Portfolio from Shionogi & Co. Ltd. in Japan
Completes acquisition of U.S. based GAVIS Pharmaceuticals LLC and Novel Laboratories Inc. (GAVIS)
Acquires Symbiomix Therapeutics, LLC in New Jersey for launch of Solosec®
Forays into the OTC Segment with pan-India launch of Softovac®
Inaugurates a new plant at Sikkim
Commissions Injectables Facility at Nagpur
Files New Drug Application for Etanercept Biosimilar in Japan
Signs deal with Illinois-based AbbVie offering exclusive rights to develop and commercialize Lupin’s MALT1 inhibitors (oncology)
Inks partnership with Boehringer Ingelheim to develop and commercialise novel oncology drug
Launches Orphan Drug NaMuscla for treatment of nondystrophic Myotonia
Receives European Marketing Authorization for Nepexto, Biosimilar Etanercept
Receives International Sustainability Rating System (ISRS) Certification for four sites
India business crosses INR 5,000 Cr.
Acquires Southern Cross Pharma in Australia
Completes the acquisition of brands from Anglo-French Drugs & Industries Limited and its Associates
Assurance Statement